Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX112 in Relapsed/Refractory Hematologic Autoimmune Disease
NCT07549698Phase 2Recruiting
- Sponsor
- CRISPR Therapeutics
- Start
- Jul 2026
- Primary completion
- Dec 2033
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 3
01
Overview
A Phase 2 trial of zugocabtagene geleucel in immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), sponsored by CRISPR Therapeutics. Started Jul 2026; status: recruiting.
02
Drugs
zugocabtagene geleucel
03
Conditions
immune thrombocytopenia (ITP)warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NCT07549698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07549698.